Into the future: Diversifying lipid management

The Lancet

Volumn 380, Issue 9858, 2012, Pages 1971-1974

  Tonkin, Andrew M ^a   Watts, Gerald F ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; AMG 145; ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; MONOTHERAPY; MUSCLE DISEASE; NOTE; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK REDUCTION;

EID: 84870494718     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61888-1     Document Type: Note

References (15)

1. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
2. Giugliano RP, Desai NR, Kohli P, et al, for the LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebocontrolled, dose-ranging, phase 2 study. Lancet 2012; published online Nov 6. http://dx.doi.org/10.1016/S0140-6736(12)61770-X.
3. Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012; published online Nov 6. http://dx.doi.org/10.1016/S0140-6736(12)61771-1.
4. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005; 19: 403-14.
5. Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 2012; 11: 367-83.
6. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that co-ordinates LDL catabolism. J Lipid Res 2009; 50 (suppl): S172-77.
7. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154-56.
8. Cohen, JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-72.
9. Dias CS, Shaywitz AJ, Wasserman SM, et al. Effect of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012; 60: 1888-98.
10. Stein EA, Gipe D, Begeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012; 380: 29-36.
11. McKenny JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilising/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012; 59: 2344-53.
12. Zhao Z, Tuakli-Wosornu, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identifi cation of a compound heterozygote. Am J Hum Genet 2006; 79: 514-23.
13. Konrad RJ, Troutt JS, Cao G. Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis 2011; 10: 38.
14. Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008; 5: 497-505.
15. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 998-1006.